Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Emily O. Dumas"'
Autor:
Aparna Vasanthakumar, Justin W Davis, Manal Abunimeh, Jonas Söderholm, Jiuhong Zha, Emily O Dumas, Daniel E Cohen, Jeffrey F Waring, Martin Lagging
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0198296 (2018)
BACKGROUND:Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Pati
Externí odkaz:
https://doaj.org/article/23916246c20f4325ac0a6eac3286f175
Autor:
Pierre Tonnerre, Maxwell Robidoux, Emily O. Dumas, Nancy S. Shulman, Jenna L. Gustafson, Raymond T. Chung, Daniel E. Cohen, Georg M. Lauer, Arthur Y. Kim, Daniel Kvistad, Sakuni T. Silva, Nadia Alatrakchi, Joelle Brown, Charles Carlton-Smith, Jacinta A. Holmes, Hongtao Zhang
Publikováno v:
Journal of Viral Hepatitis. 26:362-372
The role of the endogenous interferon (IFN) system has been well characterized during IFN-based therapy for chronic hepatitis C virus (HCV) infection; less is known for direct-acting antivirals (DAAs). In this phase 3b open-label study, we assessed c
Autor:
Emily O. Dumas, Kent D. Stewart, Michael D. Tufano, Jill Beyer, Neeta S. Panchal, Dachun Liu, Warren M. Kati, Lisa E. Hernandez, Todd W. Rockway, John K. Pratt, John T. Randolph, Clarence J. Maring, David W A Beno, G. Koev, Donner Pamela L, Yaya Liu, Motter Christopher E, Kenton L. Longenecker, Lynn Colletti, Rolf Wagner, Rubina Mondal, A. Chris Krueger, Hock B. Lim, Akhteruzzaman Molla
Publikováno v:
Journal of Medicinal Chemistry. 61:1153-1163
ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to
Autor:
Andrew H. Talal, Emily O. Dumas, Hongtao Zhang, Jennifer King, Andrew J. Ocque, Christophe Hézode, Richard M Rejman, Jiuhong Zha, Gene D. Morse, Barbara M. Bauer, Daniel E. Cohen, Nancy S. Shulman, Danijela Lucic, Jean-Michel Pawlotsky, Gavin Cloherty
Publikováno v:
The Journal of Infectious Diseases. 217:474-482
Background It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. Methods This partially randomized, open-label, phase 2 study en
Autor:
Emily O. Dumas, Tarik Asselah, Wenjing Lu, Tami Pilot-Matias, Daniel E. Cohen, Tania M. Welzel, Rawi Hazzan, Xavier Forns, Jordan J. Feld, David R. Shaw, Stefan Zeuzem
Publikováno v:
The Lancet Gastroenterology & Hepatology. 2:494-500
Clinical studies have shown high rates of sustained virological response (hepatitis C virus [HCV] RNA15 IU/mL) at post-treatment week 12 (SVR12) in patients with genotype 1b infection with and without cirrhosis who received coformulated ombitasvir, p
Autor:
Emily O. Dumas, John F. Dillon, Federico J. Mensa, Krzysztof Tomasiewicz, Christophe Hézode, Gregory J. Dore, Linda M Fredrick, Jason Grebely, Michael Gschwantler, Franco Felizarta, Brian Conway, Negar N. Alami
Publikováno v:
The International journal on drug policy. 66
International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and pibrentasvir has shown high sus
Autor:
Federico Rodriguez-Perez, Thomas Berg, Mark S. Sulkowski, Zhenzhen Zhang, Gretja Schnell, David L. Wyles, Gregory J. Dore, Jason Grebely, Erica Villa, Emily O. Dumas, Negar N. Alami, Heiner Wedemeyer, Graham R. Foster, Massimo Puoti, Curtis Cooper
Publikováno v:
Open Forum Infectious Diseases
Background We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78a52b5713cb26831270ee849dbdd567
http://hdl.handle.net/10281/304386
http://hdl.handle.net/10281/304386
Autor:
Jeffrey F. Waring, Emily O. Dumas, Daniel E. Cohen, Aparna Vasanthakumar, Martin Lagging, Jonas Söderholm, Jiuhong Zha, Manal Abunimeh, Justin W. Davis
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0198296 (2018)
PLoS ONE
PLoS ONE
Background Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Pati
Autor:
Charles S. Venuto, Marianthi Markatou, Paul K. Wallace, Gene D. Morse, Emily O. Dumas, Yvonne Woolwine-Cunningham, Rosemary L. Furlage, Andrew J. Ocque, Robin DiFrancesco, Andrew H. Talal
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
The liver is crucial to pharmacology, yet substantial knowledge gaps exist in the understanding of its basic pharmacologic processes. An improved understanding for humans requires reliable and reproducible liver sampling methods. We compared liver co
Autor:
D. Quarless, S. Abel, Arthur Y. Kim, Emily O. Dumas, C. Konefal, E. Dilmukhametova, Georg M. Lauer, Manal Abunimeh, J.W. Davis, A. Vasanthakumar, Jeffrey F. Waring, D. Cohen, R.T. Chung, K. Idler
Publikováno v:
Journal of Hepatology. 68:S134-S135